ALBO Albireo Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALBO

Price (delayed)

$31.95

Market cap

$615.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.34

Enterprise value

$438.79M

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and ...

Highlights
The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter
The gross profit has contracted by 18% YoY but it has grown by 6% from the previous quarter
The net income has dropped by 66% year-on-year and by 13% since the previous quarter
The quick ratio is down by 29% since the previous quarter and by 22% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.albireopharma.com/
Peers: OTIC ORIC

Key stats

What are the main financial stats of ALBO
Market
Shares outstanding
19.26M
Market cap
$615.22M
Enterprise value
$438.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.4
Price to sales (P/S)
66.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.48
Earnings
Revenue
$9.24M
EBIT
-$121.32M
EBITDA
-$121.13M
Free cash flow
-$120.35M
Per share
EPS
-$7.34
Free cash flow per share
-$6.27
Book value per share
$5.91
Revenue per share
$0.48
TBVPS
$10.53
Balance sheet
Total assets
$219.5M
Total liabilities
$105.99M
Debt
$9.86M
Equity
$113.5M
Working capital
$168.26M
Liquidity
Debt to equity
0.09
Current ratio
7.23
Quick ratio
6.9
Net debt/EBITDA
1.46
Margins
EBITDA margin
-1,310.7%
Gross margin
100%
Net margin
-1,468.4%
Operating margin
-1,312.8%
Efficiency
Return on assets
-50.9%
Return on equity
-82.9%
Return on invested capital
-7,283%
Return on capital employed
-63%
Return on sales
-1,312.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALBO stock price

How has the Albireo Pharma stock price performed over time
Intraday
0%
1 week
1.14%
1 month
7.14%
1 year
-2.89%
YTD
-14.82%
QTD
-9.18%

Financial performance

How have Albireo Pharma's revenue and profit performed over time
Revenue
$9.24M
Gross profit
$9.24M
Operating income
-$121.32M
Net income
-$135.7M
Gross margin
100%
Net margin
-1,468.4%
The net margin has dropped by 103% year-on-year and by 7% since the previous quarter
ALBO's operating margin has dropped by 89% year-on-year and by 8% since the previous quarter
The net income has dropped by 66% year-on-year and by 13% since the previous quarter
The company's operating income has shrunk by 55% YoY and by 14% QoQ

Growth

What is Albireo Pharma's growth rate over time

Valuation

What is Albireo Pharma stock price valuation
P/E
N/A
P/B
5.4
P/S
66.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.48
Albireo Pharma's EPS has decreased by 24% YoY and by 8% QoQ
ALBO's price to book (P/B) is 69% higher than its 5-year quarterly average of 3.2 and 29% higher than its last 4 quarters average of 4.2
The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 10058.6
The revenue has contracted by 18% YoY but it has grown by 6% from the previous quarter

Efficiency

How efficient is Albireo Pharma business performance
Albireo Pharma's return on invested capital has shrunk by 152% QoQ but it has increased by 42% YoY
Albireo Pharma's return on sales has shrunk by 99% YoY and by 8% QoQ
Albireo Pharma's return on assets has decreased by 10% YoY and by 9% QoQ
Albireo Pharma's return on equity has decreased by 9% QoQ

Dividends

What is ALBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALBO.

Financial health

How did Albireo Pharma financials performed over time
The total assets is 107% more than the total liabilities
Albireo Pharma's current ratio has decreased by 29% from the previous quarter and by 22% YoY
The quick ratio is down by 29% since the previous quarter and by 22% year-on-year
The debt is 91% smaller than the equity
The debt to equity has grown by 29% since the previous quarter but it has declined by 18% year-on-year
The equity has increased by 27% year-on-year but it has declined by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.